B+
Bull case
25%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
KTTA
Pasithea TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Two dated PAS-004 presentations could strengthen the case for further development if safety, exposure and early clinical signals remain persuasive. June advanced-cancer observations were preliminary and company-reported.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
The November NF1 presentations are initial Part A data; clinical benefit, durability and registrational relevance remain unproven.
Momentum
83
Value
56
Sentiment
72
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.39 · Bull $0.75 · Bear $0.22Analysis 2026-10-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $3.00
Why
Momentum83 · Δ7d -
Value56 · Δ7d -0.3
Sentiment72 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • The November NF1 presentations are initial Part A data; clinical benefit, durability and registrational relevance remain unproven.
- • The September 16 8-K concerned expiration and delisting of KTTAW warrants, not delisting of KTTA common stock. [#8-K-2026-09-16] SEC filing.
- • Small, early-stage datasets may not establish efficacy; weaker or ambiguous NF1 data could sharply reduce confidence in the lead program.
Catalyst clock
2026-10-23
PAS-004 advanced-cancer data at ESMO
Lead driver: Sentiment · See AI snapshot
Momentum
83
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
56
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.6
Sentiment
72
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 83.4 / Value 56.3 / Sentiment 71.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-09. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.39
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.22
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$13.28M
Beta
0.22
Shares Out
33.41M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.33
Rev YoY
-100.0%
EPS YoY
-75.1%
Gross Margin
-21.0%
Op Margin
-
Net Debt
-$55.26M
Current Ratio
26.25
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data